Search

Displaying results 4541 - 4550 of 10000 in total
  1. Drug

    Ebopiprant

    go.drugbank.com/drugs/DB16147
    Investigational

    Ebopiprant is under investigation in clinical trial NCT03369262 (Poc Study of OBE022 in Threatened Preterm Labour).

  2. Drug

    Rivenprost

    go.drugbank.com/drugs/DB16315
    Investigational

    Rivenprost is under investigation in clinical trial NCT00296556 (Therapeutic Study of ONO-4819CD for Ulcerative Colitis).

  3. Drug

    JTC-801 free base

    go.drugbank.com/drugs/DB17033
    Experimental

    An antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment.[A253027]

  4. Drug

    Suvodirsen

    go.drugbank.com/drugs/DB17940
    Investigational

    Suvodirsen is an antisense oligonucleotide that has been investigated for the treatment of Duchenne muscular dystrophy.

  5. Drug

    ART5803

    go.drugbank.com/drugs/DB18379
    Investigational

    ART5803 is a humanized one-armed monoclonal antibody with a high affinity for the NMDA receptor.

  6. Drug

    Rugonersen

    go.drugbank.com/drugs/DB18662
    Investigational

    Rugonersen is a locked nucleic acid antisense oligonucleotide under investigation for the treatment of Angelman Syndrome.

  7. Drug

    IMT-288

    go.drugbank.com/drugs/DB19068
    Investigational

    IMT-288 is under investigation in clinical trial NCT01730638 (Immunotep for Patients With Medullary Thyroid Carcinoma.).

  8. Drug

    Ensovibep

    go.drugbank.com/drugs/DB19078
    Investigational

    Ensovibep is under investigation in clinical trial NCT04501978 (ACTIV-3: Therapeutics for Inpatients With COVID-19).

  9. Drug

    AB-207

    go.drugbank.com/drugs/DB22801
    Investigational

    AB-207 is under investigation in clinical trial NCT06456073 (E-CEL UVEC Treatment for Anal Fissures).

  10. Drug

    UB-612

    go.drugbank.com/drugs/DB16444
    Investigational

    In addition, the vaccine contains a proprietary peptide UBITh®1a for enhanced immunogenicity, five identified peptides with Th or CTL epitopes to improve peptide solubility, and aluminum phosphate adjuvant … The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the